Bringing the fundamentals into focus…
Back to Integra LifeSciences Holdings Corporation
How Integra LifeSciences Holdings Corporation stacks up
IART · against 469 other Healthcare companies of similar size
Valuation
60/ 100
Above the middle of the pack.
Ranked #198 of 470 · scores higher than 57% of peers
Bars: peers in each 10-point band of the valuation score39 peers with a valuation score of 60–69, including IART · Click a bar to see the companies
Why valuation scores 60?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its EBITDA yield, which is stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -0.7% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 2.4% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 83% of peers. EBITDA yield: 11.2% vs peer median 4.0%
Metric by metric
Position: dot = IART, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | IART | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 460 reported | -0.7% | 1.3% | 41% | 30% | |
| EBITDA yieldHigher is better · 475 reported | 11.2% | 4.2% | 83% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | 1.1% | -2.5% | 66% | 20% | |
| Book yieldHigher is better · 466 reported | 98.4% | 41.3% | 89% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around IARTScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score